GPCRライブシグナル | Getagraph.comで利益を最大化

買う 137361 min ago

@ $46.21

発行日: 15 2月 2024 @ 02:06

リターン: -21.76%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: -4.71 %

Live Chart Being Loaded With Signals

Commentary (18 5月 2024 @ 05:00):

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs...

Stats
本日の出来高	426 085
平均出来高	589 165
時価総額	1.69B
EPS	$0 ( 2024-05-09 )
次の収益日	( $-0.230 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.88
ATR14	$0.0740 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Fmr Llc	Buy	0
2024-03-15	Lin Xichen	Buy	213 486	Stock Option (right to buy)
2024-03-15	Bach Mark Allen	Buy	65 352	Stock Option (right to buy)
2024-03-15	Ma Yingli	Buy	91 494	Stock Option (right to buy)
2024-03-15	Yoon Jun	Buy	148 134	Stock Option (right to buy)

INSIDER POWER
30.94
Last 43 transactions
Buy: 9 065 015 \| Sell: 6 065 489

ボリューム相関

長: 0.24 (neutral)

短: 0.47 (neutral)

Signal:(49.103) Neutral

Structure Therapeutics 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Structure Therapeutics 相関 - 通貨/商品

0.47
( neutral )

0.22
( neutral )

0.00
( neutral )

0.44
( neutral )

0.26
( neutral )

-0.47
( neutral )

Structure Therapeutics 財務諸表

Annual	2023
収益:	$0
総利益:	$-949 174 (0.00 %)
EPS:	$-2.44

FY	2023
収益:	$0
総利益:	$-949 174 (0.00 %)
EPS:	$-2.44

FY	2022
収益:	$0
総利益:	$-623 258 (0.00 %)
EPS:	$-1.400

Financial Reports:

No articles found.

Structure Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.